TearLab prices $35.1 mil public offering of common stock

Article

 

San Diego-TearLab Corp. announced the pricing of an underwritten public offering of 2,600,000 shares of its common stock at a price to the public of $13.50 per share for gross proceeds of $35.1 million.

Net proceeds from the sale of the shares will be approximately $32.6 million.  TearLab has also granted the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering to cover overallotments.

TearLab plans to use the net proceeds from this offering for commercialization of its products, research and development, working capital, and other general corporate purposes. The offering is expected to close on or about July 30, subject to the satisfaction of customary closing conditions.

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Patricia Buehler, MD, MPH, at ASCRS 2025
Brett Bielory, MD, at ASCRS 2025
At ASCRS 2025, Alex Hacopian, MD, shares information from his presentation on next-gen presbyopia-correcting intraocular lenses.
Rhue and Canto-Sims talk the value of contact lens patients, financial insights, and key benefits of implementing a contact lens management system.
Eva Kim, MD, shares visual outcomes of EVO implantable collamer lens in patients with low to moderate myopia
Drs Brianna Rhue and Diana Canto-Sims discuss the benefits of implementing a contact lens management system that can help improve lens sales at your practice.
Dr Ashley Wallace Tucker speaks on the Myopia Management Navigator.
Matt Jones, OD; Matt Burns, OD; and Joe Sugg, OD; detailed what optometrists can expect to change when HB 1353's regulations are enacted later this year.
Arkansas Optometric Association legislative cochairs Matt Jones, OD; Matt Burns, OD; and Joe Sugg, OD, discuss their involvement in their bill and provide context for its relevance.
Elise Kramer, OD, FAAO, FSLS, describes her take on a multidisciplinary approach to dry eye
© 2025 MJH Life Sciences

All rights reserved.